Completed PHASE2 INTERVENTIONAL 4-arm NCT02737397

Safety and Efficacy of a Combination Product for the Prevention of Veisalgia

A Double-blind Placebo-controlled 4-Way Crossover Study to Evaluate the Efficacy of JMI-001 (an Over-the-counter Pain Medicine and an Antihistamine) in the Prophylaxis of Veisalgia in Healthy Volunteers

Sponsor: Sen-Jam Pharmaceutical

Conditions Veisalgia

Interventions JMI-001 (SJP-304 and SJP-223) SJP-223 SJP-304 placebo

Updated 11 times since 2017 Last updated: Jul 17, 2018 Started: Mar 31, 2016 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02737397, this PHASE2 trial focuses on Veisalgia and remains completed. Sponsored by Sen-Jam Pharmaceutical, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Oct 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sen-Jam Pharmaceutical

Data source: Sen-Jam Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.